Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
31.44
+0.76 (2.48%)
Sep 18, 2024, 2:09 PM EDT - Market open
Denali Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Cash & Equivalents | 74.68 | 127.11 | 218.04 | 293.48 | 507.14 | 79.45 | Upgrade
|
| Short-Term Investments | 821.37 | 907.41 | 1,118 | 571.93 | 962.55 | 335.91 | Upgrade
|
| Cash & Short-Term Investments | 896.04 | 1,035 | 1,336 | 865.41 | 1,470 | 415.36 | Upgrade
|
| Cash Growth | -24.76% | -22.58% | 54.40% | -41.12% | 253.84% | -10.54% | Upgrade
|
| Accounts Receivable | - | 3.42 | 9.28 | - | - | - | Upgrade
|
| Other Receivables | 1.4 | - | - | 1.23 | 5.67 | - | Upgrade
|
| Receivables | 1.4 | 3.42 | 9.28 | 1.23 | 5.67 | - | Upgrade
|
| Prepaid Expenses | 30.94 | 26.21 | 26.82 | 30.6 | 20.28 | 14.68 | Upgrade
|
| Total Current Assets | 928.38 | 1,064 | 1,372 | 897.23 | 1,496 | 430.03 | Upgrade
|
| Property, Plant & Equipment | 72.61 | 71.64 | 74.52 | 69.61 | 73.46 | 80.66 | Upgrade
|
| Long-Term Investments | 450.99 | - | - | 425.45 | 32.7 | 39.89 | Upgrade
|
| Other Long-Term Assets | 50.58 | 18.14 | 13.4 | 11.87 | 2.46 | 2.66 | Upgrade
|
| Total Assets | 1,503 | 1,154 | 1,460 | 1,404 | 1,604 | 553.23 | Upgrade
|
| Accounts Payable | 13.94 | 9.48 | 2.79 | 4.78 | 1.07 | 2.59 | Upgrade
|
| Accrued Expenses | 42.59 | 61.24 | 59.37 | 47.71 | 42.46 | 20.35 | Upgrade
|
| Current Portion of Leases | 7.77 | 7.26 | 7.32 | 5.45 | 4.69 | 3.67 | Upgrade
|
| Current Unearned Revenue | - | - | 290.05 | 320.3 | 23.48 | 18.74 | Upgrade
|
| Other Current Liabilities | 10.23 | - | 4.39 | - | - | - | Upgrade
|
| Total Current Liabilities | 74.53 | 77.98 | 363.92 | 378.25 | 71.7 | 45.34 | Upgrade
|
| Long-Term Leases | 40.98 | 44.98 | 53.03 | 58.55 | 64.18 | 68.87 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 0.48 | 4.69 | 317.17 | 43.75 | Upgrade
|
| Other Long-Term Liabilities | - | - | 0.38 | 0.38 | 0.7 | 0.38 | Upgrade
|
| Total Liabilities | 115.51 | 122.96 | 417.81 | 441.87 | 453.75 | 158.34 | Upgrade
|
| Common Stock | 1.76 | 1.71 | 1.69 | 1.55 | 1.53 | 1.29 | Upgrade
|
| Additional Paid-In Capital | 2,705 | 2,145 | 2,019 | 1,608 | 1,504 | 818.8 | Upgrade
|
| Retained Earnings | -1,317 | -1,116 | -970.99 | -645 | -354.42 | -425.55 | Upgrade
|
| Comprensive Income & Other | -2.66 | 0.64 | -6.89 | -2.5 | -0.25 | 0.35 | Upgrade
|
| Total Common Equity | 1,387 | 1,031 | 1,042 | 962.29 | 1,151 | 394.89 | Upgrade
|
| Shareholders' Equity | 1,387 | 1,031 | 1,042 | 962.29 | 1,151 | 394.89 | Upgrade
|
| Total Liabilities & Equity | 1,503 | 1,154 | 1,460 | 1,404 | 1,604 | 553.23 | Upgrade
|
| Total Debt | 48.75 | 52.24 | 60.35 | 64.01 | 68.87 | 72.53 | Upgrade
|
| Net Cash (Debt) | 1,298 | 982.27 | 1,276 | 1,227 | 1,434 | 382.71 | Upgrade
|
| Net Cash Growth | 14.34% | -23.01% | 4.00% | -14.42% | 274.57% | -37.48% | Upgrade
|
| Net Cash Per Share | 8.74 | 7.15 | 10.16 | 10.10 | 12.72 | 4.00 | Upgrade
|
| Filing Date Shares Outstanding | 143.17 | 139.16 | 136.68 | 122.83 | 120.98 | 105.42 | Upgrade
|
| Total Common Shares Outstanding | 143.12 | 138.39 | 135.97 | 122.28 | 120.53 | 96.19 | Upgrade
|
| Working Capital | 853.85 | 986.16 | 1,008 | 518.99 | 1,424 | 384.69 | Upgrade
|
| Book Value Per Share | 9.69 | 7.45 | 7.67 | 7.87 | 9.55 | 4.11 | Upgrade
|
| Tangible Book Value | 1,387 | 1,031 | 1,042 | 962.29 | 1,151 | 394.89 | Upgrade
|
| Tangible Book Value Per Share | 9.69 | 7.45 | 7.67 | 7.87 | 9.55 | 4.11 | Upgrade
|
| Machinery | - | 50.35 | 37.6 | 32.97 | 26.91 | 24.44 | Upgrade
|
| Leasehold Improvements | - | 41.24 | 43.7 | 35.24 | 34.74 | 34.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.